Cargando…

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A

AIMS: Prophylactic treatment of haemophilia A patients with factor VIII (FVIII) concentrate focuses on maintaining a minimal trough FVIII activity level to prevent bleeding. However, due to differences in bleeding tendency, the pharmacokinetic (PK)‐guided dosing approach may be suboptimal. An altern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bukkems, Laura H., Valke, Lars L. F. G., Barteling, Wideke, Laros‐van Gorkom, Britta A. P., Blijlevens, Nicole M. A., Cnossen, Marjon H., van Heerde, Waander L., Schols, Saskia E. M., Mathôt, Ron A. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304184/ https://www.ncbi.nlm.nih.gov/pubmed/34921439 http://dx.doi.org/10.1111/bcp.15185

Ejemplares similares

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma
por: Maas, Dominique, et al.
Publicado: (2018)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

Interspecies comparison of simultaneous thrombin and plasmin generation
por: Tarandovskiy, Ivan D., et al.
Publicado: (2020)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021)

Thrombin adhesive properties: induction by plasmin and heparan sulfate
Publicado: (1993)

Thrombin and Plasmin Alter the Proteome of Neutrophil Extracellular Traps
por: Lim, Chun Hwee, et al.
Publicado: (2018)

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
por: Verhagen, Marieke J. A., et al.
Publicado: (2022)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

Platelet CD34 expression in a patient with a partial deletion of transcription factor subunit CBFB
por: van Bergen, Maaike G.J.M., et al.
Publicado: (2020)

Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype
por: Atiq, Ferdows, et al.
Publicado: (2022)

THE ROLE OF A CONTAMINANT IN THROMBIN IN THE HUMAN PLASMIN ASSAY SYSTEM
por: Siegel, Malcolm, et al.
Publicado: (1957)

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
por: Goedhart, Tine M. H. J., et al.
Publicado: (2021)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Adhesive Virulence Factors of Staphylococcus aureus Resist Digestion by Coagulation Proteases Thrombin and Plasmin
por: Risser, Fanny, et al.
Publicado: (2022)

The SLIM study—Shared medical appointments to change lifestyles of overweight people with haemophilia: A randomized multiple baseline (n‐of‐1) design
por: Hendriks, Marcel A. L., et al.
Publicado: (2021)

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data
por: Eichler, Hermann, et al.
Publicado: (2018)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation
por: de Laat-Kremers, Romy M. W., et al.
Publicado: (2021)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Pregnancy outcome in afibrinogenemia: Are we giving enough fibrinogen concentrate? A case series
por: Saes, Joline L., et al.
Publicado: (2020)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o43l3sblfi7pvqsa4ovr0ji91b